nach oben

Erschienen in:

01.06.2019 | Review Article

Intranasal therapy with opioids for children and adolescents with cancer: results from clinical studies

verfasst von: Silvia Triarico, Michele Antonio Capozza, Stefano Mastrangelo, Giorgio Attinà, Palma Maurizi, Antonio Ruggiero

Erschienen in: Supportive Care in Cancer | Ausgabe 10/2019

Einloggen, um Zugang zu erhalten

Abstract

Opioids are essential for the treatment of pain, which is a serious symptom for children and adolescents affected by cancer. Intranasal opioids may be very useful for the treatment of breakthrough pain in children and adolescents with cancer, for their little invasiveness, ease of administration, rapid onset of action, and high bioavailability. Intranasal drug delivery may be influenced by anatomical and physiological factors (nasal mucosa absorption area, mucociliary clearance, enzymatic activity, anatomical anomalies, chronic or inflammatory alterations of nasal mucosa), drug-related factors (molecular weight, solubility), and delivery device. Fentanyl is a lipophilic opioid commonly proposed for intranasal use among pediatric patients, but no studies have been conducted yet about intranasal use of other available opioids for management of pediatric cancer pain. In this review, we analyze several elements which may influence absorption of intranasal opioids in children and adolescents, with a focus on pharmacokinetics and therapeutic aspects of each opioid currently available for intranasal use.

Mercadante S (2004) Cancer pain management in children. Palliat Med 18:654–662CrossRefPubMed

Ruggiero A, Coccia P, Arena R, Maurizi P, Battista A, Ridola V, Attinà G, Riccardi R (2013) Efficacy and safety of transdermal buprenorphine in the management of children with cancer-related pain. Pediatr Blood Cancer 60:433–437CrossRefPubMed

Murphy A, O'Sullivan R, Wakai A et al (2014) Intranasal fentanyl for the management of acute pain in children. Cochrane Database Syst Rev 10(10):CD009942. https://doi.org/10.1002/14651858.CD009942.pub2 CrossRef

Del Pizzo J, Callahan JM (2014) Intranasal medications in pediatric emergency medicine. Pediatr Emerg Care 30(7):496–501; quiz 502–4. https://doi.org/10.1097/PEC.0000000000000171

Morrison EE, Costanzo RM (1990) Morphology of the human olfactory epithelium. J Comp Neurol 297(1):1–13CrossRefPubMed

Salib RJ, Harries PG, Nair SB, Howarth PH (2008) Mechanisms and mediators of nasal symptoms in non-allergic rhinitis. Clin Exp Allergy 38(3):393–404CrossRefPubMed

Newman SP, Morén F, Clarke SW (1987) Deposition pattern from a nasal pump spray. Rhinology 25(2):77–82PubMed

Wolfe TR, Braude DA (2010) Intranasal medication delivery for children: a brief review and update. Pediatrics 126(3):532–537CrossRefPubMed

Costantino HR, Illum L, Brandt G, Johnson PH, Quay SC (2007) Intranasal delivery: physicochemical and therapeutic aspects. Int J Pharm 337(1–2):1–24CrossRefPubMed

10.

Arora P, Sharma S, Garg S (2002) Permeability issues in nasal drug delivery. Drug Discov Today 7(18):967–975CrossRefPubMed

11.

Kurkov SV, Loftsson T (2013) Cyclodextrins. Int J Pharm 453(1):167–180CrossRefPubMed

12.

Jiang L, Gao L, Wang X, Tang L, Ma J (2010) The application of mucoadhesive polymers in nasal drug delivery. Drug Dev Ind Pharm 36(3):323–336CrossRefPubMed

13.

Zhang X, Zhang QY, Liu D et al (2005) Expression of cytochrome p450 and other biotransformation genes in fetal and adult human nasal mucosa. Drug Metab Dispos 33:1423–1428CrossRefPubMed

14.

Pandey RK, Bahetwar SK, Saksena AK, Chandra G (2011) A comparative evaluation of drops versus atomized administration of intranasal ketamine for the procedural sedation of young uncooperative pediatric dental patients: a prospective crossover trial. J Clin Pediatr Dent Fall 36(1):79–84CrossRef

15.

Leow KP, Smith MT, Watt JA, Williams BE, Cramond T (1992) Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration. Ther Drug Monit 14:479–484CrossRefPubMed

16.

Tong X, Dong J, Shang Y, Inthavong K, Tu J (2016) Effects of nasal drug delivery device and its orientation on sprayed particle deposition in a realistic human nasal cavity. Comput Biol Med 1(77):40–48CrossRef

17.

Mercadante S, Portenoy RK (2016) Breakthrough cancer pain: twenty-five years of study. Pain 157(12):2657–2663CrossRefPubMed

18.

Westerling D, Persson C, Hoglund P (1995) Plasma concentrations of morphine, morphine-3-glucuronide, and morphine-6-glucuronide after intravenous and oral administration to healthy volunteers: relationship to nonanalgesic actions. Ther Drug Monit 17:287–301CrossRefPubMed

19.

Illum L, Watts P, Fisher AN et al (2002) Intranasal delivery of morphine. J Pharmacol Exp Ther 301:391–400CrossRefPubMed

20.

Pavis H, Wilcock A, Edgecombe J, Carr D, Manderson C, Church A, Fisher A (2002) Pilot study of nasal morphine–chitosan for the relief of breakthrough pain in patients with cancer. J Pain Symptom Manag 24:598–602CrossRef

21.

Stoker DG, Reber KR, Waltzman LS, Ernst C, Hamilton D, Gawarecki D, Mermelstein F, McNicol E, Wright C, Carr DB (2008) Analgesic efficacy and safety of morphine–chitosan nasal solution in patients with moderate to severe pain following orthopedic surgery. Pain Med 9:3–12CrossRefPubMed

22.

Takala A, Kaasalainen V, Seppala T, Kalso E, Olkkola KT (1997) Pharmacokinetic comparison of intravenous and intranasal administration of oxycodone. Acta Anaesthesiol Scand 41:309–312CrossRefPubMed

23.

Lofwall MR, Moody DE, Fang WB, Nuzzo PA, Walsh SL (2012) Pharmacokinetics of intranasal crushed OxyContin and intravenous oxycodone in nondependent prescription opioid abusers. J Clin Pharmacol 52:600–606CrossRefPubMed

24.

Coda BA, Rudy AC, Archer SM, Wermeling DP (2003) Pharmacokinetics and bioavailability of single-dose intranasal hydromorphone hydrochloride in healthy volunteers. Anesth Analg 97:117–123CrossRefPubMed

25.

Wermeling DP, Clinch T, Rudy AC, Dreitlein D, Suner S, Lacouture PG (2010) A multicenter, open-label, exploratory doseranging trial of intranasal hydromorphone for managing acute pain from traumatic injury. J Pain 11:24–31CrossRefPubMed

26.

Kaasa S, Moksnes K, Nolte T et al (2010) Pharmacokinetics of intranasal fentanyl spray in patients with cancer and breakthrough pain. J Opioid Manag 6:17–26CrossRefPubMed

27.

Kress HG, Oronska A, Kaczmarek Z et al (2009) Efficacy and tolerability of intranasal fentanyl spray 50 to 200 microg for breakthrough pain in patients with cancer: a phase III, multinational, randomized, doubleblind, placebo-controlled, crossover trial with a 10-month, open-label extension treatment period. Clin Ther 31:1177–1191CrossRefPubMed

28.

Christrup LL, Foster D, Popper L, Troen T, Upton R (2008) Pharmacokinetics, efficacy, and tolerability of fentanyl following intranasal versus intravenous administration in adults undergoing third-molar extraction: a randomized, double-blind, double-dummy, two-way, cross-over study. Clin Ther 30:469–481CrossRefPubMed

29.

Fisher A, Watling M, Smith A, Knight A (2010) Pharmacokinetics and relative bioavailability of fentanyl pectin nasal spray 100–800 mcg in healthy volunteers. Int J Clin Pharmacol Ther 48:860–867CrossRefPubMed

30.

Fisher A, Watling M, Smith A, Knight A (2010) Pharmacokinetic comparisons of three nasal fentanyl formulations; pectin, chitosan and chitosan–poloxamer 188. Int J Clin Pharmacol Ther 48:138–145CrossRefPubMed

31.

Nave R, Sides EH, Colberg T et al. (2009) Pharmacokinetics of intranasal fentanyl spray (INFS) in subjects with common cold. 6th congress of the European federation of IASP chapters, Lisbon

32.

Borland ML, Bergesio R, Pascoe EM, Turner S, Woodger S (2005) Intranasal fentanyl is an equivalent analgesic to oral morphine in paediatric burns patients for dressing changes: a randomised double blind crossover study. Burns 31:831–837CrossRefPubMed

33.

Mudd S (2011) Intranasal fentanyl for pain management in children: a systematic review of the literature. J Pediatr Healthcare 25:316–322CrossRef

34.

Hansen MS, Mathiesen O, Trautner S et al (2012) Intranasal fentanyl in the treatment of acute pain: a systematic review. Acta Anaesthesiol Scand 56:407–419CrossRefPubMed

35.

Verghese ST, Hannallah RS, Brennan M, Yarvitz JL, Hummer KA, Patel KM, He J, McCarter R (2008) The effect of intranasal administration of remifentanil on intubating conditions and airway response after sevoflurane induction of anesthesia in children. Anesth Analg 107:1176–1118CrossRefPubMed

36.

Lundeberg S, Roelofse JA (2011) Aspects of pharmacokinetics and pharmacodynamics of sufentanil in pediatric practice. Paediatr Anaesth 21(3):274–279CrossRefPubMed

37.

Karl HW, Keifer AT, Rosenberge JL et al (1992) Comparison of the safety and efficacy of intranasal midazolam or sufentanil for preinduction of anesthesia in pediatric patients. Anesthesiology 76(2):209–215CrossRefPubMed

38.

Zedie N, Amory DW, Wagner BK, O’Hara DA (1996) Comparison of intranasal midazolam and sufentanil premedication in pediatric outpatients. Clin Pharmacol Ther 59(3):341–348CrossRefPubMed

39.

Nielsen BN, Friis SM, Romsing J et al (2014) Intranasal sufentanil/ketamine analgesia inchildren. Paediatr Anaesth 24(2):170–180CrossRefPubMed

40.

Barton ED, Colwell CB, Wolfe T, Fosnocht D, Gravitz C, Bryan T, Dunn W, Benson J, Bailey J (2005) Efficacy of intranasal naloxone as a needleless alternative for treatment of opioid overdose in the prehospital setting. J Emerg Med 29:265–271CrossRefPubMed

41.

Dowling J, Isbister GK, Kirkpatrick CM, Naidoo D, Graudins A (2008) Population pharmacokinetics of intravenous, intramuscular, and intranasal naloxone in human volunteers. Ther Drug Monit 30:490–496PubMed

42.

Vanky E, Hellmundt L, Bondesson U, Eksborg S, Lundeberg S (2017) Pharmacokinetics after a single dose of naloxone administered as a nasal spray in healthy volunteers. Acta Anaesthesiol Scand 61(6):636–640CrossRefPubMed

Titel: Intranasal therapy with opioids for children and adolescents with cancer: results from clinical studies
verfasst von: Silvia Triarico
Michele Antonio Capozza
Stefano Mastrangelo
Giorgio Attinà
Palma Maurizi
Antonio Ruggiero
Publikationsdatum: 01.06.2019
Verlag: Springer Berlin Heidelberg
Erschienen in: Supportive Care in Cancer / Ausgabe 10/2019
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-019-04854-6

Springer Medizin

Intranasal therapy with opioids for children and adolescents with cancer: results from clinical studies

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2019

Assessment of quality of life, information, and supportive care needs in patients with muscle and non-muscle invasive bladder cancer across the illness trajectory

Health concerns of cancer survivors after primary anti-cancer treatment

A feasibility study examining the impact of yoga on psychosocial health and symptoms in pediatric outpatients receiving chemotherapy

Development of the MASCC/ISOO clinical practice guidelines for mucositis: an overview of the methods

Psychostimulants for cancer-related cognitive impairment in adult cancer survivors: a systematic review and meta-analysis

Adherence and quality of life in women with breast cancer being treated with oral hormone therapy

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie